Funding Opportunities

• NIAID Clinical Trial Planning Grant (R34 Clinical Trials Not Allowed)
  (PAR-20-270)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): September 14, 2020; January 12, 2021; May 12, 2021; September 14, 2021; January 12, 2022; May 13, 2022; September 14, 2022; January 13, 2023; May 12, 2023
• Cooperative Research Agreements Related to the World Trade Center Health Program (U01)
  (PAR-20-280)
  National Institute for Occupational Safety and Health
  Application Receipt Date(s): December 8, 2020; December 7, 2021; December 6, 2022; December 5, 2023; December 10, 2024 On-time submission requires that electronic applications be error-free and made available to CDC for processing from eRA Commons on or before the deadline date. Applications must be submitted to and validated successfully by Grants.gov/eRA Commons no later than 5:00 PM Eastern Time on the listed application due date. Applicant organizations are strongly encouraged to start the registration process at least 4 weeks prior to the application due date Note: HHS/CDC grant submission procedures do not provide a period of time beyond the application due date to correct any error or warning notices of noncompliance with application instructions that are identified by Grants.gov or eRA systems (i.e., error correction window).
• Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional)
  (PAR-20-286)
  National Institute of Mental Health
  Application Receipt Date(s): October 19, 2020, June 18, 2021 and February 18, 2022 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed)
  (PAR-20-294)
  National Cancer Institute
  Application Receipt Date(s): November 12, 2020; April 9, 2021; November 9, 2021; April 7, 2022; November 9, 2022
• Maternal and Pediatrics Precision in Therapeutics Hub (MPRINT) (P30 Clinical Trial Not Allowed)
  (RFA-HD-21-025)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): November 30, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Maternal and Pediatrics Precision in Therapeutics Hub (MPRINT) (P50 Clinical Trial Optional)
  (RFA-HD-21-026)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): November 30, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Systematic Characterization of Genomic Variation on Genomic Function and Phenotype (UM1 Clinical Trial Not Allowed)
  (RFA-HG-20-043)
  National Human Genome Research Institute
  Application Receipt Date(s): November 4, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Defining Genomic Influence on Gene Network Regulation (U01 Clinical Trial Not Allowed)
  (RFA-HG-20-044)
  National Human Genome Research Institute
  Application Receipt Date(s): November 4, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Single-cell Profiling of Regulatory Element and Gene Activity in Relationship to Genome Function (UM1 Clinical Trial Not Allowed)
  (RFA-HG-20-045)
  National Human Genome Research Institute
  Application Receipt Date(s): November 4, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Genomic Variation and Function Data and Administrative Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-HG-20-046)
  National Human Genome Research Institute
  Application Receipt Date(s): November 4, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Developing Predictive Models of the Impact of Genomic Variation on Function (U01 Clinical Trial Not Allowed)
  (RFA-HG-20-047)
  National Human Genome Research Institute
  Application Receipt Date(s): November 4, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional)
  (RFA-MH-20-600)
  National Institute of Mental Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  Application Receipt Date(s): July 14, 2021, July 14, 2022, and July 14, 2023 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement.
• Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD (R01 Clinical Trial Not Allowed)
  (RFA-NS-21-006)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): October 27, 2020
• Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)
  (RFA-OD-20-014)
  National Institutes of Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Cancer Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): September 15,2020 No late applications will be accepted for this Funding Opportunity Announcement
• Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed)
  (RFA-OD-20-015)
  National Institutes of Health
  National Institute of General Medical Sciences
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  National Library of Medicine
  Application Receipt Date(s): September 15, 2020 No late applications will be accepted for this Funding Opportunity Announcement
• Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)
  (RFA-OD-20-016)
  National Institutes of Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of General Medical Sciences
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Library of Medicine
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): September 30, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
• Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)
  (RFA-OD-20-017)
  National Institutes of Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Dental and Craniofacial Research
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Heart, Lung, and Blood Institute
  National Library of Medicine
  National Center for Advancing Translational Sciences
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Minority Health and Health Disparities
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): September 18, 2020 N?o late applications will be accepted for this Funding Opportunity Announcement.
• Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)
  (RFA-OD-20-018)
  National Institutes of Health
  National Institute on Aging
  National Cancer Institute
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Center for Advancing Translational Sciences
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): September 18, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
• Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)
  (RFA-OD-20-019)
  National Institutes of Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute of General Medical Sciences
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Heart, Lung, and Blood Institute
  National Library of Medicine
  National Institute of Nursing Research
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  Office of Behavioral and Social Sciences Research
  National Institute on Minority Health and Health Disparities
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): September 30, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
• Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)
  (RFA-OD-20-020)
  National Institutes of Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Dental and Craniofacial Research
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Heart, Lung, and Blood Institute
  National Library of Medicine
  National Center for Advancing Translational Sciences
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Minority Health and Health Disparities
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): September 18, 2020
• Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed)
  (RFA-OD-20-021)
  National Institutes of Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Dental and Craniofacial Research
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Heart, Lung, and Blood Institute
  National Library of Medicine
  National Center for Advancing Translational Sciences
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Minority Health and Health Disparities
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): September 18, 2020
• Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)
  (RFA-OD-20-022)
  National Institutes of Health
  National Institute on Aging
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Library of Medicine
  National Institute of Nursing Research
  National Institute of Neurological Disorders and Stroke
  Office of Research on Women's Health
  Application Receipt Date(s): September 15, 2020, by 5:00 PM local time of applicant organization. . No late applications will be accepted for this Funding Opportunity Announcement.
• Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)
  (RFA-OD-20-023)
  National Institutes of Health
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Heart, Lung, and Blood Institute
  National Center for Advancing Translational Sciences
  John E. Fogarty International Center
  National Institute on Minority Health and Health Disparities
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): September 30, 2020. No late applications will be accepted for this Funding Opportunity Announcement.
• Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)
  (RFA-TR-20-003)
  National Center for Advancing Translational Sciences
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): Applications will be accepted on a rolling basis, beginning on August 6, 2020. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.